Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma (SART)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by Comprehensive Cancer Centers of Nevada
Sponsor:
Collaborator:
Comprehensive Cancer Centers of Nevada
Information provided by (Responsible Party):
Wolfram Samlowski, Comprehensive Cancer Centers of Nevada
ClinicalTrials.gov Identifier:
NCT01565837
First received: March 26, 2012
Last updated: January 28, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2017
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)